Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer

被引:10
作者
de Boer, Pieter T. [1 ]
Frederix, Geert W. J. [2 ]
Feenstra, Talitha L. [3 ,4 ]
Vemer, Pepijn [1 ,3 ]
机构
[1] Univ Groningen, Dept Pharm PharmacoTherapy Epidemiol & Econ PTEE, Groningen, Netherlands
[2] Univ Utrecht, Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, POB 30-001, NL-9700 RB Groningen, Netherlands
[4] Natl Inst Publ Hlth & Environm RIVM, Ctr Nutr Prevent & Hlth Serv Res, Bilthoven, Netherlands
关键词
COST-EFFECTIVENESS ANALYSIS; ADJUVANT TRASTUZUMAB THERAPY; AGED; 50-64; YEARS; POSTMENOPAUSAL WOMEN; VACCINATION PROGRAM; TECHNOLOGY-ASSESSMENT; ENDOCRINE THERAPY; PREGNANT-WOMEN; CYCLOPHOSPHAMIDE TAC; UTILITY ANALYSIS;
D O I
10.1007/s40273-016-0410-3
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background Transparent reporting of validation efforts of health economic models give stakeholders better insight into the credibility of model outcomes. In this study we reviewed recently published studies on seasonal influenza and early breast cancer in order to gain insight into the reporting of model validation efforts in the overall health economic literature. Methods A literature search was performed in Pubmed and Embase to retrieve health economic modelling studies published between 2008 and 2014. Reporting on model validation was evaluated by checking for the word validation, and by using AdViSHE (Assessment of the Validation Status of Health Economic decision models), a tool containing a structured list of relevant items for validation. Additionally, we contacted corresponding authors to ask whether more validation efforts were performed other than those reported in the manuscripts. Results A total of 53 studies on seasonal influenza and 41 studies on early breast cancer were included in our review. The word validation was used in 16 studies (30 %) on seasonal influenza and 23 studies (56 %) on early breast cancer; however, in a minority of studies, this referred to a model validation technique. Fifty-seven percent of seasonal influenza studies and 71 % of early breast cancer studies reported one or more validation techniques. Cross-validation of study outcomes was found most often. A limited number of studies reported on model validation efforts, although good examples were identified. Author comments indicated that more validation techniques were performed than those reported in the manuscripts. Conclusions Although validation is deemed important by many researchers, this is not reflected in the reporting habits of health economic modelling studies. Systematic reporting of validation efforts would be desirable to further enhance decision makers' confidence in health economic models and their outcomes.
引用
收藏
页码:833 / 845
页数:13
相关论文
共 118 条
  • [1] Aboutorabi Ali, 2014, Glob J Health Sci, V7, P98, DOI 10.5539/gjhs.v7n1p98
  • [2] Model performance evaluation (validation and calibration) in model-based studies of therapeutic interventions for cardiovascular diseases: A review and suggested reporting framework
    Haji Ali Afzali H.
    Gray J.
    Karnon J.
    [J]. Applied Health Economics and Health Policy, 2013, 11 (2) : 85 - 93
  • [3] Cost-Effectiveness Analysis of Intraoperative Radiation Therapy for Early-Stage Breast Cancer
    Alvarado, Michael D.
    Mohan, Aron J.
    Esserman, Laura J.
    Park, Catherine C.
    Harrison, Brittany L.
    Howe, Rebecca J.
    Thorsen, Cristina
    Ozanne, Elissa M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (09) : 2873 - 2880
  • [4] An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
    Antonio Buendia, Jefferson
    Vallejos, Carlos
    Pichon-Riviere, Andres
    [J]. BIOMEDICA, 2013, 33 (03): : 411 - 417
  • [5] Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada
    Attard, C. L.
    Pepper, A. N.
    Brown, S. T.
    Thompson, M. F.
    Thuresson, P. -O.
    Yunger, S.
    Dent, S.
    Paterson, A. H.
    Wells, G. A.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 173 - 188
  • [6] Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects
    Au, Heather-Jane
    Golmohammadi, Kamran
    Younis, Tallal
    Verma, Shailendra
    Chia, Stephen
    Fassbender, Konrad
    Jacobs, Philip
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2009, 114 (03) : 579 - 587
  • [7] Health and economic impact of the seasonal influenza vaccination programme in England
    Baguelin, Marc
    Jit, Mark
    Miller, Elizabeth
    Edmunds, William John
    [J]. VACCINE, 2012, 30 (23) : 3459 - 3462
  • [8] Economic Value of Seasonal and Pandemic Influenza Vaccination during Pregnancy
    Beigi, Richard H.
    Wiringa, Ann E.
    Bailey, Rachel R.
    Assi, Tina-Marie
    Lee, Bruce Y.
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 49 (12) : 1784 - 1792
  • [9] Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium
    Blommaert, Adriaan
    Bilcke, Joke
    Vandendijck, Yannick
    Hanquet, Germaine
    Hens, Niel
    Beutels, Philippe
    [J]. VACCINE, 2014, 32 (46) : 6075 - 6083
  • [10] Economic evaluation of smoking-cessation therapies: A critical and systematic review of simulation models
    Kristian Bolin
    [J]. PharmacoEconomics, 2012, 30 (7) : 551 - 564